Details

Autor(en) / Beteiligte

• Muluhngwi, Penn
• Klinge, Carolyn M

Titel

Roles for miRNAs in endocrine resistance in breast cancer

Ist Teil von

• Endocrine-related cancer, 2015-10, Vol.22 (5), p.R279-R300

Ort / Verlag

England: Bioscientifica Ltd

Erscheinungsjahr

2015

Quelle

EZB-FREE-00999 freely available EZB journals

Beschreibungen/Notizen

• Therapies targeting estrogen receptor alpha (ERα), including selective ER modulators such as tamoxifen, selective ER downregulators such as fulvestrant (ICI 182 780), and aromatase inhibitors such as letrozole, are successfully used in treating breast cancer patients whose initial tumor expresses ERα. Unfortunately, the effectiveness of endocrine therapies is limited by acquired resistance. The role of microRNAs (miRNAs) in the progression of endocrine-resistant breast cancer is of keen interest in developing biomarkers and therapies to counter metastatic disease. This review focuses on miRNAs implicated as disruptors of antiestrogen therapies, their bona fide gene targets and associated pathways promoting endocrine resistance.